ATTOAttovia Therapeutics, Inc.
Partial data20.83USD+4.99%Mkt Cap: 950.92M $P/E: —1d ago
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed…
Industry Peers
Biotechnology$130.53BUSDP/E 30.0
$82.77BUSDP/E 19.9
$72.88BUSD
$57.82BUSDP/E 37.5
$59.94BUSDP/E 36.7
$44.25BUSDP/E 18.9
$41.64BUSDP/E 65.8
$41.34BUSD
$33.81BUSDP/E 31.5
$33.67BUSDP/E 43.8
$27.61BUSD
$26.38BUSD
$25.73BUSDP/E 16.2
$25.34BUSD
$21.66BUSDP/E 28.0
$20.41BUSDP/E 27.6
$15.63BUSDP/E 18.5
$15.62BUSDP/E 16.5
$14.41BUSDP/E 18.3
$13.66BUSD
Key Statistics
Company
Market Cap950.92M $
Enterprise Value216.93M $
Revenue (TTM)1.35M $
Gross Profit-57.61M $
Net Income (TTM)-60.63M $
Revenue/Share0.3340 USD
Last Price20.83 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees44
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-3.09
EV/Revenue160.69
P/S—
P/B-0.71
EPS (TTM)-2.50
EPS (Forward)—
52W Range
18.5054% of range22.79
52W High22.79 USD
52W Low18.50 USD
Profitability
Gross Margin0.00%
Oper. Margin-5260.00%
EBITDA Margin0.00%
Profit Margin-4490.89%
ROE56.43%
ROA-36.55%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-59.20M $
CapEx (TTM)2.31M $
FCF Margin—
FCF Yield—
Net Debt-127.82M $
Net Debt/EBITDA1.82
Balance Sheet
Debt/Equity-0.05
Current Ratio13.94
Quick Ratio13.61
Book Value/Sh-27.8240 USD
Cash/Share29.40 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.43.03M
Float2.81M
Insiders23.70%
Institutions40.79%
Technical
SMA 5019.74 (+5.5%)
SMA 20019.74 (+5.5%)
Beta—
S&P 52W Chg20.92%
Avg Vol (30d)1.24M
Avg Vol (10d)1.06M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—